PRESS RELEASE: ImaRx Therapeutics Announces Pricing of Its IPO

TUCSON, Ariz. -- ImaRx Therapeutics, Inc. announced today the initial public offering of 3,000,000 shares of common stock at a price of $5 per share. All shares are being offered by ImaRx Therapeutics. In addition, ImaRx Therapeutics has granted the underwriters a 45-day option to purchase up to an additional 450,000 shares to cover over-allotments, if any. Maxim Group LLC acted as sole book-running manager and I-Bankers Securities, Inc. acted as co-manager for the offering. ImaRx Therapeutics’ common stock will trade on the NASDAQ Capital Market under the symbol "IMRX."

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 25, 2007. Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the offering may be obtained from: Maxim Group Syndicate Department: 405 Lexington Ave., New York, NY, 10174; by telephone 212-895-3575, Fax 212-895-3828 or email request at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction.

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company developing and commercializing therapies for vascular disorders. The Company’s research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology. ImaRx Therapeutics’ commercialization efforts are currently focused on its product, Abbokinase®, for the treatment of acute massive pulmonary embolism.

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.